Louis Jammayrac

Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage.

Founded in September 2005 by Dr Roger LAHANA, CEO, and Karine LARBOURET, Director of Operations, Neorphys is a company which discovers and develops novel, proprietary analgesic drug candidates with low side effects, especially with regard to gastro-intestinal transit. This is why the most advanced drug candidate is developed for visceral pain management. Beside the co-founders, Neorphys scientists, all PhD's or equivalent, share a strong expertise in opioids and acute pain as well as in behavioral pharmacology. They have a proven track record of success in using discovery techniques such as medicinal chemistry, cell biology, toxicology and relevant animal assays.